US FDA puts Idenix's HCV candidates on clinical hold
This article was originally published in Scrip
Executive Summary
The US FDA has put two of Idenix's hepatitis C virus candidates onto clinical hold, due to three cases of elevated liver enzyme levels in a Phase I drug-interaction study in healthy volunteers. IDX184, a nucleotide inhibitor, and IDX320, a protease inhibitor, are being developed both individually and in combination for HCV.